Moderna reported an upward revision to its 2025 revenue outlook, now targeting between $7.5 billion and $8.1 billion, compared with its prior range of $6.3 billion to $7.0 billion. This represents a year-over-year increase of approximately 20% to 25% and surpasses analysts’ consensus by more than $500 million. Management attributed the boost to stronger-than-expected demand for its influenza and cytomegalovirus vaccine candidates, underscoring resilience beyond its flagship COVID-19 portfolio.

The company confirmed a strengthened liquidity profile, with cash, cash equivalents and marketable securities totaling roughly $6.4 billion at the end of Q4. This cash balance, combined with projected free cash flow generation of over $2.0 billion in 2025, is expected to fund ongoing operations and late-stage trials through mid-2027 without the need for additional equity financing. Moody’s recently affirmed Moderna’s credit rating at B2, citing improved cash flows and disciplined spending.

For fiscal 2026, Moderna outlined revenue guidance in the range of $8.3 billion to $9.0 billion, reflecting anticipated launches of its next-generation respiratory syncytial virus (RSV) candidate and expanded uptake of its combination mRNA flu/COVID booster. R&D expenses are projected to increase by approximately 10% as the company initiates two pivotal studies and readies regulatory submissions for potential approvals in Europe and Asia. Operating margin is expected to modestly expand by 100 basis points due to higher fixed-cost leverage.

Moderna highlighted a robust development slate, with at least four late-stage readouts scheduled through 2026, including Phase III data for its universal flu vaccine and pivotal initiation of its cytomegalovirus program. Early-stage programs in oncology and rare genetic disorders are set to enter first-in-human trials, bringing the total number of active clinical candidates to 25. The company expects these catalysts to meaningfully diversify its revenue base over the next three years.